Corteria Management Team
Philip Janiak, CEO
Philip received his PhD degree in Cardiovascular Pharmacology from the University of Iowa, USA (1989) and graduated from the Faculty of Pharmacy (Paris XI University) in 1984. He started his career at Servier where he contributed to the discovery of ivabradine as a co-inventor. Until the end of 2020 he was the head of Cardiovascular Research at Sanofi focusing on the development of new treatments in selected areas of unmet medical need where emerging science and a better understanding of human disease biology can be intersected with heart failure at the core. During his career he developed a long standing experience in the management of international R&D groups and in leading multiple research collaborations with biotechs (ie. MyoKardia) and academic institutions (ie. IMI).
Marie-Laure Ozoux, CSO
Marie-Laure Ozoux has 30-years of experience in worldwide healthcare industry in both preclinical and clinical drug development (oncology, immunology, cardiovascular…) with particular expertise in development of biotherapeutics. She successfully contributed to the development of drugs such as Lovenox, Sarclisa… She held senior roles in a diverse array of activities including large group management with multiple teams dedicated to biomarkers and biological analyses from genes to proteins and research project head. Marie-Laure is a graduate of the University of Paris V (Docteur en Pharmacie) with a specialization in pharmacokinetics from the same university and MBA from IAE (Institut d'Administration des Entreprises de Paris)
Régis Olivier, CFO
Regis brings more than 30 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Corteria, Regis was CEO of Axess Vision Technology, a company dedicated to the development of single-use medical endoscopes where he led the launch of new products and successfully completed new financing rounds. Also former CFO of Echosens, a medical technology company specializing in the non-invasive detection of liver disease, he completed the structuring and sale of the company in 2011. Previously, he held several positions as a financial analyst and financial controller in several industrial companies. R�gis holds a Master degree in Management and Finance from EDC Paris
Mark Kowala, Scientific Advisor
Mark has 30 years of drug discovery and early development experience in CV disease. Until 2021 he was CSO of CardioRenal drug discovery at Lilly Research Laboratories. Mark built an expert team which produced a portfolio of heart failure and dyslipidemia assets now in clinical development. He fostered external collaborations for human target validation and managed Biotech partnerships. Previously he was Senior Director of CV at Pfizer and a Research Scientist at BMS. Mark received his PhD at the Australian National University, Canberra, Australia.
Scientific advisory board
Pr Alexandre Mebazaa, MD, PhD
Department of Anaesthesiology, Burn and Critical Care, Saint Louis-Lariboisière University Hospitals, AP-HP, Paris, France
Co-author of the European Society of Cardiology guidelines for acute heart failure Principal investigator in numerous clinical trials in heart failure
Pr Adriaan Voors, MD, PhD
Adriaan Voors is Professor of Cardiology and specializes in heart failure. Currently, Professor Voors is Director of the Heart Failure Clinic of the Department of Cardiology of the University Medical Center Groningen. Professor Voors supervised 44 PhD students, mainly on heart failure related topics. He is an editorial board member of the European Journal of Heart Failure, Clinical Research in Cardiology, Cardiovascular Drugs and Therapy, the Journal of Cardiovascular Medicine, and Heart Failure Reviews. He is/was involved as principal investigator/executive/steering committee member of 49 clinical trials on novel therapies in acute and chronic heart failure. Prof. Voors was the co-chair of the 2016 ESC Heart Failure Guidelines. He has (co-) authored 690 peer-reviewed papers and several books and chapters, his Hirsch-index is 97.
Pr Frank Ruschitzka MD, PhD
Professor & Chairman, Department of Cardiology, University H
Translational research, from the development of novel drugs and devices to randomized clinical trials in heart failure Deputy Editor, European Heart Journal